Assessment of PENG Block as a Part of Multimodal Analgesia Following Hip Surgeries.
- Conditions
- Anesthesia
- Interventions
- Drug: Pericapsular nerve group (PENG) blockOther: Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.
- Registration Number
- NCT06916000
- Lead Sponsor
- Ain Shams University
- Brief Summary
to study the effect of Pericapsular nerve group (PENG) block as a part of multimodal analgesia regimen for hip arthroplasties
- Detailed Description
PENG block is a novel block described by Giron-Arango in 2018 to anesthesize the anterior hip capsule as it is supplied by branches from femoral, obturator and accessory obturator nerves, sparing motor function is an additional significance So currently the block is used to reduce post operative opioid consumption, delay time rescue analgesia, facilitate positioning for spinal anesthesia for hip surgeries and to accelerate mobility and so hospital discharge saving this vulnerable group of patient from any hospital acquired pneumonia, decreasing hospital stays, and improving recovery times would provide valuable insights into its cost-effectiveness and long-term benefits for healthcare system Our primary outcome to be studied is pain assessment via Numer Rating Scale over 24 hours postoperatively, in addition to to secondary outcomes including the aforementioned advantages.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 50
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PENG block group (25 particiants) Pericapsular nerve group (PENG) block For postoperative pain management, all patients of this arm will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango. In addition, multimodal analgesia will be given including IV paracetamol 1000 mg BID and oral celecoxib tablet 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as demand dose and when the NRS pain score was equal to or greater than 4 points. Group C: control group (25 participants) Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine. Patients will receive only other multimodal analgesics
- Primary Outcome Measures
Name Time Method Pain score: pain assessment using a Numeric Rating System (NRS) immediately in the postoperative period. 24 hours Pain score: pain intensity will be evaluated using a Numeric Rating System (NRS) immediately in the postoperative period, every 2 hours during the first 6 hours and then every 6 hours till 24 hours postoperatively. Scores ranging from 0 to 10, with 0 indicating the absence of pain and 10 indicating the worst possible pain.
- Secondary Outcome Measures
Name Time Method Rescue analgesia timing and opioid consumption over 24 hours 24 hours Time to first opioid demand and total opioid consumed by each patient individually over 24 hours.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Faculty of medicine, Ain Shams University
🇪🇬Abbasia, Cairo, Egypt
Faculty of medicine, Ain Shams University🇪🇬Abbasia, Cairo, Egypt